LONG-TERM EFFECTIVENESS OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA IN CLINICAL PRACTICE

M.D. GIL-SIERRA¹, M.D.P. BRICEÑO-CASADO², C. MORENO-ROMAS³, E. RIOS-SANCHEZ³, J.M. BORRERO-RUBIO³
¹HOSPITAL UNIVERSITARIO PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN
²HOSPITAL NUESTRA SEÑORA DEL PRADO, PHARMACY, TALAVERA DE LA REINA, SPAIN
³HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN

BACKGROUND
Omalizumab is a monoclonal antibody used in patients with antihistaminic refractory chronic idiopathic urticaria (CIU). Real-life data on the long-term effectiveness of omalizumab could provide relevant information for healthcare professionals.

AIM
To evaluate the long-term effectiveness of omalizumab in CIU in clinical practice.

MATERIAL AND METHODS
Descriptive retrospective study between October 2020 and June 2021.

DATA: Farmatools® application and digital clinical history
- Gender
- Age
- Previous therapy
- Duration of treatment
- Regimen with omalizumab

Baseline Urticaria Activity Score during a 7-day period (UAS7).

EFFECTIVENESS
0 6 30 60 months

RESULTS
- Patients: 47 patients
- Gender: 23.4% were male and 76.6% were female
- Age: median of 45 (11-76) years.
- Previous therapy: all patients received H1 antihistamines and 72.3% were treated with corticosteroids.
- Duration of treatment with omalizumab: median of 18 (11-56) months.
- Omalizumab regimens:
  → 19.1% of patients were treated with 150 mg/28 days
  → 78.7% of patients received 300 mg/28 days
  → 2.2% were treated with 450 mg/28 days
- Baseline UAS7: All patients presented NR at baseline (UAS7 >15).

Definitions for effectiveness
- No response to therapy (NR): UAS7 >15.
- Mild disease (MD): UAS7 = 7-15.
- Adequate disease control (DC): UAS7 ≤ 6.
- Total response (TR): UAS7 = 0.
- Patients with NR and omalizumab therapy suspension in a certain month were considered as NR in the following months.

Baseline UAS7
NR: 5.7%
MD: 14.3%
DC: 5.7%
TR: 74.3%

UAS7
NR: 6.7%
MD: 6.7%
DC: 40%
TR: 46.6%

UAS7
NR: 28.6%
MD: 0%
DC: 28.6%
TR: 42.8%

EFFECTIVENESS
0 6 30 60 months

CONCLUSION
Omalizumab showed long-term effectiveness in CIU patients, maintaining almost half of the patients with total response and almost a third of patients with adequate disease control at 60 months.

CONTACT DATA
E-mail: mangilsie@yahoo.com